Disease Information & Support


The Word:


Generic name Ofatumumab
Pronunciation oh-fah-TOO-moo-mab
Brand name(s), other common name(s) Arzerra®
Drug type  Monoclonal antibody
How the drug is given Intravenously (IV)

Ofatumumab is FDA approved to treat people who have chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab. It is also approved in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL), for whom fludarabine-based therapy is considered inappropriate.

Side effects needing medical attention: Fever; cough; diarrhea; rash; neutropenia (abnormally low white blood count); fatigue; pneumonia; anemia; trouble breathing; nausea; infusion reactions; and upper respiratory tract infection.

In patients with prior hepatitis B (HBV) infection, HBV reactivation may occur when the body's immune system is impaired.

For information on how to manage the costs of drug therapy, please see Financial Matters and Prescription Drug Coverage, or to speak with an Information Specialist, call (800) 955-4572.

last updated on Tuesday, April 22, 2014